financetom
Business
financetom
/
Business
/
Snap beats profit estimates on strength in advertising platform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Snap beats profit estimates on strength in advertising platform
Feb 4, 2025 1:28 PM

Feb 4 (Reuters) - Snap beat Wall Street

estimates for quarterly profit on Tuesday, benefitting from

improvements to the Snapchat parent's advertising platform that

has also helped it cut spending.

The company has been making investments in artificial

intelligence and machine learning tools in recent years to help

in automated placement of ads, create personalized ads.

That has helped Snap tap small- and mid-sized advertisers,

making them the largest contributor to the company's ad revenue

growth in 2024.

The company will roll out Sponsored Snaps, video ads that

appear in users' inboxes and Promoted Places, a feature that

highlights business locations on Snap Map, to additional

markets.

Snap has been focusing on direct response ads that are

designed to prompt specific actions like app downloads or

website visits, at a time when the company grapples with

weakness in brand awareness ads in recent years.

It faces stiff competition from the likes of TikTok and

Meta-owned Facebook and Instagram, which have become the go-to

platforms for advertisers because of their larger user base.

The company said it would grow its fulltime headcount by 8%

to 10% this year.

Snap reported adjusted earnings per share of 16 cents for

the fourth quarter ended Dec. 31, beating analysts' average

estimate of 14 cents, according to data compiled by LSEG.

Daily active users of Snapchat increased 9% year-over-year

to 453 million in the quarter, beating estimates of 450.8

million.

The company forecasts first-quarter revenue to be between

$1.33 billion and $1.36 billion, the mid-point of which was

slightly above analysts' average estimate of $1.33 billion.

It expects adjusted EBITDA (earnings before interest, taxes,

depreciation and amortization) of $40 million to $75 million in

the first quarter, below expectations of $78.1 million.

Revenue in the fourth quarter grew 14% year-over-year to

$1.56 billion, marginally beating the average estimate of $1.55

billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's Taisho Pharma faces claim over buyout price in court, Nikkei reports
Japan's Taisho Pharma faces claim over buyout price in court, Nikkei reports
Jul 14, 2024
July 15 (Reuters) - Investment funds Curi RMB Capital and Oasis Management are contesting the pricing of Taisho Pharmaceutical Holdings' ( TAIPY ) management buyout in court after failed negotiations over their forced divestment as minority shareholders, Nikkei newspaper reported on Monday. Taisho's founding family gained 73% of the company in a tender offer in January for 8,620 yen per...
Trump-victory trades to swell after shooting, investors say
Trump-victory trades to swell after shooting, investors say
Jul 14, 2024
SINGAPORE (Reuters) -Saturday's shooting at U.S. former President Donald Trump's election rally raises his odds of winning back the White House, and trades betting on his victory will increase this coming week, investors said on Sunday. Trump was shot in the ear during the rally in Pennsylvania on Saturday in what the authorities were treating as an assassination attempt. Trump,...
A Look At Upcoming IPOs For The Week
A Look At Upcoming IPOs For The Week
Jul 14, 2024
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week. TWFG, Inc (NASDAQ:TWFG) becomes publicly listed starting on July 18, 2024. The company has a price range set between $14.00 and...
BRIEF-Japan's Taisho Pharma Faces Claim Over Buyout Price From Curi RMB, Oasis - Nikkei
BRIEF-Japan's Taisho Pharma Faces Claim Over Buyout Price From Curi RMB, Oasis - Nikkei
Jul 14, 2024
July 15 (Reuters) - Taisho Pharmaceutical Holdings Co Ltd ( TAIPY ): * JAPAN'S TAISHO PHARMA FACES CLAIM OVER BUYOUT PRICE FROM CURI RMB, OASIS * CURI RMB CAPITAL AND OASIS MANAGEMENT CONTESTING PRICING OF TAISHO PHARMACEUTICAL MANAGEMENT BUYOUT IN COURT Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved